Inclusion Criteria:

- 18 years of age or older.

- Histologically or cytologically confirmed adenocarcinoma of prostate that is
metastatic, hormone-refractory (confirmed by testing serum testosterone), and
clinically progressive following at least one prior hormonal regimen.

- Patients must have documented progression of disease on anti-androgen withdrawal, if
the patient have documented progression on previous anti-androgen therapy.

- Measurable (patient with measurable bi-dimensional disease) or evaluable disease
(defined as the presence of a nonmeasurable abnormality on CT or on physical
examination coupled with a PSA ³ 30).

- Karnofsky performance status ³ 60%.6. Adequate bone marrow functions: Granulocyte
count 1,000/mm3, Platelets 75,000/mm3, haemoglobin 8 g/dl.

- Adequate renal and liver functions: Creatinine < 1.5 mg/dl, Bilirubin < 2 mg/dl,
ALT/AST less than 2.5 times the upper limit of the reference range for the institute.

- Patients with chemical or clinical hypothyroidism should have their thyroid
replacement prior to starting study.

- Patients must have recovered from the effect of recent surgery (at least 4 weeks
apart), radiotherapy (at least 4 weeks apart).

- Patients have ability to complete Quality of Life (QoL) questionnaires.

- Patients must sign informed consent.

Exclusion Criteria:

- Patients with advanced second primary malignancy.

- Patients with brain metastases.

- Patients with hypersensitivity to thalidomide.

- History of myocardial infarction within past 6 months, uncontrolled congestive heart
failure or angina pectoris.

- Patients with orthostatic hypotension before therapy.

- Patients with NCI CTC grade 3 or greater peripheral neuropathy of any cause that is
clinically detectable.

- Patients with active infection, including positive serology for HIV.

- Patients who have received chemotherapy before for treatment of metastases of
prostate cancer, or received other investigational agents or corticosteroids within 4
weeks prior to enrollment of study.